Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 692 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sham Treatment Location Clear all

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Epilepsy, Status Epilepticus, Epilepsia Partialis Continua, Epilepsia Partialis Continua, Refractory (Medically)
Interventions: Low frequency repeated TMS (LF-rTMS); Device
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dravet Syndrome
Interventions: Clobazam, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 1 Year to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more

Conditions: Alcohol Use Disorder (AUD)
Interventions: TMS; Device
Lead sponsor: Nicholas Balderston, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Wernersville, Pennsylvania

Conditions: Multiple Sclerosis, Cognitive Deficits, Gilenya Modifying Therapy for MS
Interventions: plasticity-based computerized cognitive remediation program, Gileyna; Other · Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Peripheral Neuropathy, HIV, AIDS, HIV Infections
Interventions: Acupuncture/Moxibustion; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Post-polypectomy Bleeding, Polypectomy, Elective Colonoscopy
Interventions: Hemoclip Placement, NO hemoclip placement; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 11,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 3
States / cities: Dallas, Texas • San Antonio, Texas • Temple, Texas

Conditions: Pertrochanteric Fracture
Interventions: Marcaine, Duramorph , ketorolac, Bupivacaine (Marcaine), General Anesthetics; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Optic, Atrophy, Hereditary, Leber
Interventions: GS010, Sham Intravitreal Injection; Biological · Device
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Opiate Addiction
Interventions: Depot naltrexone, Treatment as Usual (TAU); Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Wound Heal
Interventions: Free Gingival Graft Procedure; Procedure
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
Interventions: Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline, Marcaine; Procedure · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Spinal Manipulation, Sham Spinal Manipulation; Other
Lead sponsor: Palmer College of Chiropractic; Other
Eligibility: 21 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Davenport, Iowa

Conditions: Migraine
Interventions: Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain
Interventions: Intravenous acetominophen, Ketorolac, intramuscular, Bupivacaine, subcutaneous, Normal saline; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
Interventions: Otoband, Placebo device; Device
Lead sponsor: Otolith Labs; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cartilage Injury
Interventions: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation, Control group incision; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Overactive Bladder
Interventions: TheraNova Neuromodulation System; Device
Lead sponsor: Theranova, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Sacramento, California • Stanford, California

Conditions: Post Operative Pain
Interventions: Group A-Paravertebral block, Group B- No block; Drug · Other
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Attention Bias Modification (ABM), Attention control training (ACT); Behavioral
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Sickle-Beta Zero Thalassemia
Interventions: SCD-101; Drug
Lead sponsor: Invenux, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Knee Arthropathy
Interventions: Placement of an adductor canal nerve block; Procedure
Lead sponsor: Drexel University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Actinic Keratoses
Interventions: Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo; Drug · Other
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 24
States / cities: Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more

Conditions: Covid19, Stage 1 Acute Kidney Injury
Interventions: MIB-626, Placebo, Home Treatment; Drug · Other
Lead sponsor: Metro International Biotech, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Repeated TMS at Low Frequencies to Reduce Seizure Occurrence

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

iTBS for Alcohol Use Disorder

Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya

Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV

Risk of Post-polypectomy Bleeding With Prophylactic Hemoclipping

Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site

Effects of StellaLife Oral Care Recovery Kit on Palatal Wound Healing After Free Gingival Graft

Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy

Chiropractic for Hypertension in Patients

A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

Multimodal Pain Management for Cesarean Delivery

Prevention of Unmitigated Chemotherapy-induced Emesis

Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation

Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms

Paravertebral Block for Percutaneous Nephrolithotomy

Attention-Bias Modification Treatment for PTSD

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

Defining the Optimal Location to Place an Adductor Canal Block

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

Phase 2a MIB-626 vs. Placebo COVID-19